capecitabine
Showing 1 - 25 of 1,000
Breast Cancer Trial in Beijing (Mitoxantrone HCl liposome, Capecitabine)
Not yet recruiting
- Breast Cancer
- Mitoxantrone hydrochloride liposome
- Capecitabine
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Dec 1, 2023
Pancreas Cancer, Pancreas Adenocarcinoma Trial in Cleveland (Capecitabine)
Not yet recruiting
- Pancreas Cancer
- Pancreas Adenocarcinoma
- Capecitabine
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Seidman Cancer Ce
Oct 29, 2023
Recurrent Metastatic Nasopharyngeal Carcinoma Trial (Mitoxantrone HCl liposome injection, Capecitabine)
Not yet recruiting
- Recurrent Metastatic Nasopharyngeal Carcinoma
- Mitoxantrone hydrochloride liposome injection
- Capecitabine
- (no location specified)
Jan 29, 2023
Triple Negative Breast Cancer, Residual Disease Trial (Tetrathiomolybdate, Capecitabine, Pembrolizumab)
Not yet recruiting
- Triple Negative Breast Cancer
- Residual Disease
- Tetrathiomolybdate
- +2 more
- (no location specified)
Nov 15, 2023
Gastrointestinal Cancer Trial (Capecitabine, Sacituzumab govetican)
Not yet recruiting
- Gastrointestinal Cancer
- Capecitabine
- Sacituzumab govetican
- (no location specified)
Oct 2, 2023
Metastatic Colorectal Cancer Trial in Guangzhou (Cetuximab, Capecitabine)
Recruiting
- Metastatic Colorectal Cancer
- Cetuximab
- Capecitabine
-
Guangzhou, Guangdong, ChinaThe Sixth Affiliated Hospital of Sun Yat-sen University
Mar 7, 2023
Advanced Gastric Carcinoma Trial in Dhaka (Trastuzumab, Oxaliplatin, Capecitabine)
Completed
- Advanced Gastric Carcinoma
- Trastuzumab
- +2 more
-
Dhaka, BangladeshBangabandhu Sheikh Mujib Medical University
Aug 15, 2023
HER2 Positive Metastatic Breast Cancer Trial in Beijing (pyrotinib, , Capecitabine)
Active, not recruiting
- HER2 Positive Metastatic Breast Cancer
- pyrotinib
- +2 more
-
Beijing, China307 Hospital Affiliated to Academy Military Medical Science
Oct 24, 2022
Colorectal Cancer, Colorectal Cancer Stage IV Trial (Fruquintinib Plus Capecitabine, Capecitabine)
Not yet recruiting
- Colorectal Cancer
- Colorectal Cancer Stage IV
- Fruquintinib Plus Capecitabine
- Capecitabine
- (no location specified)
Jul 9, 2022
Breast, Metastatic, Triple Negative Trial in Gainesville, Jacksonville (Capecitabine, Sarilumab 150mg or 200 mg plus
Active, not recruiting
- Breast
- +4 more
- Capecitabine
- +2 more
-
Gainesville, Florida
- +1 more
Feb 2, 2023
Hormone Receptor-positive Breast Cancer Trial in Tampa (Cemiplimab, Capecitabine)
Recruiting
- Hormone Receptor-positive Breast Cancer
- Cemiplimab
- Capecitabine
-
Tampa, FloridaMoffitt Cancer Center
Dec 30, 2022
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer Trial in Australia, China
Recruiting
- Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
- LBL-007
- +3 more
-
Benowa, Queensland, Australia
- +7 more
Jan 30, 2023
Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction Trial run by the NCI (Paclitaxel, Capecitabine, BardPort
Recruiting
- Gastric Adenocarcinoma
- +3 more
- Paclitaxel
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)
Active, not recruiting
- Breast Cancer
- Capecitabine
- Aromatase Inhibitor
-
Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Sun Yat-sen Uni
Jan 27, 2023
Triple Negative Breast Cancer Trial in Guangzhou (Capecitabine, Tucidinostat)
Recruiting
- Triple Negative Breast Cancer
- Capecitabine
- Tucidinostat
-
Guangzhou, Guangdong, ChinaSun-yat sen university cancer center
Nov 1, 2022
Recurrent Pituitary Adenomas Trial in New York (Capecitabine, Temozolomide)
Terminated
- Recurrent Pituitary Adenomas
- Capecitabine
- Temozolomide
-
New York, New YorkWeill Cornell Medical College
Jul 15, 2022
Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct Trial run by the National Cancer Institute (NCI) (oxaliplatin,
Not yet recruiting
- Biliary Cancer
- +2 more
- oxaliplatin
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
May 13, 2023
Metastatic Breast Cancer Trial in Kansas City, Rochester, Saint Louis (ATI-2231, Capecitabine, Denosumab)
Not yet recruiting
- Metastatic Breast Cancer
- ATI-2231
- +3 more
-
Kansas City, Kansas
- +2 more
Mar 16, 2023
Cholangiocarcinoma, Intrahepatic Trial in Shanghai (Capecitabine, PD-1 Antibody(Tislelizumab))
Recruiting
- Cholangiocarcinoma, Intrahepatic
- Capecitabine
- PD-1 Antibody(Tislelizumab)
-
Shanghai, ChinaLulu@Huashan.Org.Cn
Aug 16, 2022
Capecitabine Versus S-1 as Adjuvant Therapy in Biliary Tract
Recruiting
- Biliary Tract Neoplasms
- +3 more
- S-1
- Capecitabine
-
Shanghai, ChinaHuashan hospital
Aug 16, 2022
Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma Trial in Frankfurt am Main (Durvalumab,
Recruiting
- Biliary Tract Cancer (CCA)
- +4 more
- Durvalumab
- +2 more
-
Frankfurt am Main, GermanyKrankenhaus Nordwest
Jun 23, 2022
Metastatic Pancreatic Adenocarcinoma Trial (Ivaltinostat, Capecitabine)
Not yet recruiting
- Metastatic Pancreatic Adenocarcinoma
- Ivaltinostat
- Capecitabine
- (no location specified)
Feb 10, 2022
Nasopharyngeal Carcinoma Trial in Guangzhou (Sintilimab, Capecitabine)
Recruiting
- Nasopharyngeal Carcinoma
- Sintilimab
- Capecitabine
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 5, 2022